Association of CD34+Cell Dose with Progression-free Survival after Allogeneic Peripheral Blood Hematopoietic Cell Transplantation in Children with Hematologic Malignancies

被引:0
作者
Wang, Yi-Lun [1 ]
Chang, Tsung-Yen [1 ,2 ]
Hsieh, Hsin-Yi [3 ]
Chen, Shih-Hsiang [1 ,2 ]
Wen, Yu-Chuan [4 ]
Chiu, Chia-Chi [4 ]
Jaing, Tang-Her [1 ,2 ,5 ]
机构
[1] Linkou Chang Gung Mem Hosp, Dept Pediat, Taoyuan, Taiwan
[2] Linkou Chang Gung Mem Hosp, Div Hematol Oncol, Taoyuan, Taiwan
[3] Kaohsiung Chang Gung Mem Hosp, Dept Hematol Oncol, Dept Pediat, Kaohsiung, Taiwan
[4] Linkou Chang Gung Mem Hosp, Dept Nursing, Taoyuan, Taiwan
[5] Chang Gung Univ, Chang Gung Childrens Hosp, Dept Pediat, Div Hematol & Oncol, 5 Fu Shin St, Taoyuan 33305, Taiwan
关键词
ACUTE MYELOID-LEUKEMIA; UNRELATED DONOR; DISEASE; IMPACT;
D O I
10.1016/j.transproceed.2023.01.005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. A higher CD34+ cell dose is associated with improved engraftment but may also be associated with an increased risk of complications after allogeneic hematopoietic stem cell transplantation, including graft-versus-host disease (GVHD). Methods. We retrospectively analyze the impact of CD34+ cell dose on OS, PFS, neutrophil engraftment, platelet engraftment, treatment-related mortality, and GVHD grading.Results. For analyses, CD34+ cell dose was stratified into low (< 8.5 pound 106/kg) and high (> 8.5 pound 106/kg). A subgroup analysis of higher CD34+ cell dose leads to prolonged OS and PFS, but statistical significance was achieved only for PFS (OR 0.36; 95%CI 0.14-0.95; P= 0.04).Conclusions. This study reinforced that CD34+ cell dose at the time of allo-HSCT retained a positive impact on PFS.
引用
收藏
页码:481 / 484
页数:4
相关论文
共 17 条
[1]   Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years [J].
Bazarbachi, Ali ;
Schmid, Christoph ;
Labopin, Myriam ;
Beelen, Dietrich ;
Blau, Igor Wolfgang ;
Potter, Victoria ;
Niittyvuopio, Riitta ;
Socie, Gerard ;
Blaise, Didier ;
Sanz, Jaime ;
Ciceri, Fabio ;
Abou Dalle, Iman ;
Spyridonidis, Alexandros ;
Bug, Gesine ;
Esteve, Jordi ;
Savani, Bipin N. ;
Nagler, Arnon ;
Mohty, Mohamad .
CLINICAL CANCER RESEARCH, 2020, 26 (24) :6475-6482
[2]   Survival of Patients with Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Study [J].
Bejanyan, Nelli ;
Weisdorf, Daniel J. ;
Logan, Brent R. ;
Wang, Hai-Lin ;
Devine, Steven M. ;
de Lima, Marcos ;
Bunjes, Donald W. ;
Zhang, Mei-Jie .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (03) :454-459
[3]   Bone Marrow Harvest in Pediatric Sibling Donors: Role of Granulocyte Colony-Stimulating Factor Priming and CD34+ Cell Dose [J].
Furey, Aimee ;
Rastogi, Sonal ;
Prince, Remi ;
Jin, Zhezhen ;
Smilow, Elana ;
Briamonte, Courtney ;
Kahn, Justine M. ;
Tanhehco, Yvette ;
Patel, Nita ;
George, Diane ;
Garvin, James ;
Bhatia, Monica ;
Satwani, Prakash .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (02) :324-329
[4]   High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia [J].
Gunn, N ;
Damon, L ;
Varosy, P ;
Navarro, W ;
Martin, T ;
Ries, C ;
Linker, C .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2003, 9 (10) :643-648
[5]   Impact of infused CD34+stem cell dosing for allogeneic peripheral blood stem cell transplantation with post-transplant cyclophosphamide [J].
Hany, Elmariah ;
Naqvi, Syeda Mahrukh Hussnain ;
Kim, Jongphil ;
Nishihori, Taiga ;
Mishra, Asmita ;
Perez, Lia ;
Faramand, Rawan ;
Lazaryan, Aleksandr ;
Liu, Hien D. ;
Khimani, Farhad ;
Nieder, Michael ;
Anasetti, Claudio ;
Pidala, Joseph ;
Bejanyan, Nelli .
BONE MARROW TRANSPLANTATION, 2021, 56 (07) :1683-1690
[6]   Immunotherapy for Acute Myeloid Leukemia: Allogeneic hematopoietic cell transplantation is here to stay [J].
Kaleka, Guneet ;
Schiller, Gary .
LEUKEMIA RESEARCH, 2022, 112
[7]   Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide [J].
Kanakry, Christopher G. ;
Bolanos-Meade, Javier ;
Kasamon, Yvette L. ;
Zahurak, Marianna ;
Durakovic, Nadira ;
Furlong, Terry ;
Mielcarek, Marco ;
Medeot, Marta ;
Gojo, Ivana ;
Smith, B. Douglas ;
Kanakry, Jennifer A. ;
Borrello, Ivan M. ;
Brodsky, Robert A. ;
Gladstone, Douglas E. ;
Huff, Carol Ann ;
Matsui, William H. ;
Swinnen, Lode J. ;
Cooke, Kenneth R. ;
Ambinder, Richard F. ;
Fuchs, Ephraim J. ;
de Lima, Marcos J. ;
Andersson, Borje S. ;
Varadhan, Ravi ;
O'Donnell, Paul V. ;
Jones, Richard J. ;
Luznik, Leo .
BLOOD, 2017, 129 (10) :1389-1393
[8]   A higher number of infused CD34+ cells has a positive impact on the clinical outcome after related PBSC transplantation [J].
Maie, K. ;
Fuji, S. ;
Tajima, K. ;
Tatsuno, M. ;
Yamagata, S. ;
Takahashi, N. ;
Ueda, R. ;
Hashimoto, H. ;
Takano, K. ;
Inoue, Y. ;
Ito, A. ;
Hayashi, Y. ;
Okinaka, K. ;
Kurosawa, S. ;
Kim, S-W ;
Tanosaki, R. ;
Heike, Y. ;
Yamashita, T. ;
Fukuda, T. .
BONE MARROW TRANSPLANTATION, 2014, 49 (08) :1113-1115
[9]   Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide [J].
McCurdy, Shannon R. ;
Kanakry, Christopher G. ;
Tsai, Hua-Ling ;
Kasamon, Yvette L. ;
Showel, Margaret M. ;
Bolanos-Meade, Javier ;
Huff, Carol Ann ;
Borrello, Ivan ;
Matsui, William H. ;
Brodsky, Robert A. ;
Ambinder, Richard F. ;
Bettinotti, Maria P. ;
Fuchs, Ephraim J. ;
Rosner, Gary L. ;
Jones, Richard J. ;
Luznik, Leo .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (02) :343-352
[10]   Donor lymphocyte infusions in AML and MDS: Enhancing the graft-versus-leukemia effect [J].
Orti, Guillermo ;
Barba, Pere ;
Fox, Laura ;
Salarnero, Olga ;
Bosch, Francesc ;
Valcarcel, David .
EXPERIMENTAL HEMATOLOGY, 2017, 48 :1-11